Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Beyond MariTide, Amgen's pipeline includes other promising candidates such as rocatinlimab for atopic dermatitis, Uplizna for generalized myasthenia gravis, and fipaxalparant for idiopathic ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Amgen’s acquisition of Horizon Therapeutics in 2023 added several rare disease drugs, such as Tepezza, Krystexxa and Uplizna, to AMGN’s portfolio. Tepezza sales rose 3% year over year to $460 ...